NCT05694715 2026-03-17
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco
Phase 1 Recruiting
Clinical Trials
109 trialsNCT07194044 2026-03-16
METTSEO
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT05733689 2026-03-10
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
University of California, Irvine
Phase 1 Recruiting
NCT05722327 2026-03-04
Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02021422 2026-02-18
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy
Baylor Research Institute
Phase 1 Completed
NCT05412082 2026-02-06
SMART TNT
University of Miami
Phase 1 Recruiting
NCT05421897 2026-01-29
RAPID
Children's Hospital Los Angeles
Phase 1 Active not recruiting
NCT07363408 2026-01-23
Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1 Not yet recruiting
NCT03290937 2026-01-06
Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT05400603 2025-12-26
Aflac-NBL-2002
Emory University
Phase 1 Recruiting
NCT01858168 2025-12-19
Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma
Massachusetts General Hospital
Phase 1 Completed
NCT05417386 2025-11-18
FOLFIRINOX + NIS793 in Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Terminated
NCT02192359 2025-11-14
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04361708 2025-10-01
I-FLOAT
University of Chicago
Phase 1 Recruiting
NCT01787500 2025-09-09
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07027748 2025-07-14
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT04920032 2025-04-08
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
University of California, Irvine
Phase 1 Recruiting
NCT05379790 2025-04-01
Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin
Erasmus Medical Center
Phase 1 Completed
NCT06760117 2025-01-06
UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors
Sun Yat-sen University
Phase 1 Recruiting
NCT05049863 2024-12-05
Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Washington University School of Medicine
Phase 1 Terminated
NCT05620862 2024-07-09
Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors
Sun Yat-sen University
Phase 1 Active not recruiting
NCT04074343 2024-02-02
TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
University of California, Irvine
Phase 1 Completed
NCT01859858 2023-12-04
Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT00876993 2023-07-03
Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Johns Hopkins All Children's Hospital
Phase 1 Completed
NCT02333188 2023-05-31
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
University of Chicago
Phase 1 Completed
NCT01528046 2023-01-13
Metformin in Children With Relapsed or Refractory Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02049593 2022-09-26
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT04173325 2022-06-14
Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer
Augusta University
Phase 1 Terminated
NCT02596503 2022-02-15
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
University of Colorado, Denver
Phase 1 Completed
NCT00695201 2021-07-01
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02368860 2021-06-01
OXIRI
National Cancer Centre, Singapore
Phase 1 Completed
NCT02645864 2021-03-18
Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma
Peking University
Phase 1 Completed
NCT00786669 2021-02-10
VITAC
Children's Hospital Medical Center, Cincinnati
Phase 1 Completed
NCT02392793 2021-02-09
Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02044120 2021-01-12
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma
Sarcoma Alliance for Research through Collaboration
Phase 1 Completed
NCT03139331 2021-01-05
PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma
University of California, San Francisco
Phase 1 Completed
NCT02906059 2020-10-12
Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer
NYU Langone Health
Phase 1 Completed
NCT01643499 2020-05-08
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
University of Chicago
Phase 1 Completed
NCT00062842 2020-03-04
Study of Irinotecan on a Weekly Schedule in Children
Baylor College of Medicine
Phase 1 Completed
NCT02148549 2019-10-07
FIRINOX
Wakayama Medical University
Phase 1 Completed
NCT02387138 2019-08-22
SIRINOX
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1 Completed
NCT00002902 2019-03-13
Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01923337 2019-01-04
Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
University of California, Davis
Phase 1 Completed
NCT00671801 2018-11-13
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00215501 2018-11-02
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00003867 2018-09-10
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
Montefiore Medical Center
Phase 1 Completed
NCT01383538 2017-08-08
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
University of California, San Francisco
Phase 1 Completed
NCT00644696 2017-07-06
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT00654160 2017-05-25
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
Mayo Clinic
Phase 1 Completed
NCT00143533 2017-04-26
Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors
St. Jude Children's Research Hospital
Phase 1 Completed